Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(14%)
Results Posted
80%(4 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
3
43%
Ph phase_1
4
57%

Phase Distribution

4

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
3(42.9%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
1
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (57.1%)
Phase 23 (42.9%)

Trials by Status

completed571%
recruiting114%
terminated114%

Recent Activity

1 active trials
Showing 5 of 7
recruitingphase_1

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368
completedphase_2

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

NCT03828747
completedphase_2

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

NCT03977584
completedphase_1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

NCT04566003
terminatedphase_2

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT05464368Phase 1

R21 Roche: 3-Way Tau Tracers in AD

Recruiting
NCT03828747Phase 2

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

Completed
NCT03977584Phase 2

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Completed
NCT04566003Phase 1

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Completed
NCT03289143Phase 2

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

Terminated
NCT04394845Phase 1

A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants

Completed
NCT02640092Phase 1

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7